BARCELONA, Feb 28 (Reuters) - Spanish drugmaker Grifols increased its annual net profit by 10% to 208 million euros ($220.19 million) as blood plasma procurement grew by more than 25%, and said it expects its ebitda to rise significantly in 2023.

Grifols, which uses blood plasma to make drugs, on Tuesday reported total revenue of 6 billion euros, up 23% from 2021, more than half of which was generated in the United States and Canada. Its earnings before interest, taxes, depreciation and amortization (ebitda) rose 27% year-on-year to €1.2 billion.

Reported net profit was below Refinitiv's estimate of €280 million, revenues were slightly higher, while its ebitda was in line with estimates.

The Barcelona-based company, which was hit hard at the start of the pandemic due to plasma shortages, expects its ebitda to rise to €1.7 billion in 2023, while its total revenue will increase by 8% to 10%, which would be a lower rate than in 2022.

Grifols said it had achieved its 2022 targets.

"Looking ahead to 2023, we believe the company has a solid foundation on which to build its future," its two co-chief executives, Victor Grifols and Raimon Grifols, said in a statement, noting that the company had to take "difficult but necessary steps."

Grifols announced earlier this month that it would cut about 2,300 jobs, 8.5% of its global workforce, as part of a review of its strategy aimed at achieving annual savings of about 400 million euros.

A week after the announcement, it said Steven F. Mayer had resigned as its executive chairman due to health and other personal reasons, and would be replaced by Thomas Glanzmann, who had served as vice chairman of the board since 2017.

($1 = €0.9446)

(Reporting by Joan Faus; edited in Spanish by Flora Gómez)